حدد سهمًا أو عملة مشفرة في شريط البحث للحصول على ملخص
Anixa Biosciences Inc
ANIXAnixa Biosciences, Inc., a clinical-stage biotechnology company, focuses on the treatment and prevention of cancer. Its therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR- T, known as chimeric endocrine receptor T-cell (CER-T) technology. The company's vaccine portfolio includes a novel vaccine being developed in collaboration with Cleveland Clinic to prevent breast cancer " primarily triple negative breast cancer (TNBC), the lethal form of the disease, as well as a vaccine to prevent ovarian cancer. Its vaccine technologies focus on immunizing against retired proteins that found to be expressed in certain forms of cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California. Address: 3150 Almaden Expressway, San Jose, CA, United States, 95118
Analytics
سعر الهدف في وول ستريت
8.5 USDنسبة السعر إلى الأرباح
–العائد الربحي
–السنة الحالية
العام الماضي
الربع الحالي
الربع الأخير
السنة الحالية
العام الماضي
الربع الحالي
الربع الأخير
الشخصيات الرئيسية ANIX
تحليلات الأرباح ANIX
نمو الأرباح على مدى 5 سنوات
–النمو المستمر
–معدل الدفع 5 سنوات في المتوسط
–تاريخ الأرباح ANIX
تقييم الأسهم ANIX
المالية ANIX
نتائج | 2019 | ديناميات |